Published in Medical Letter on the CDC and FDA, July 11th, 2004
The X-ACT (Xeloda in adjuvant colon cancer therapy) study successfully met its primary endpoint in demonstrating that disease-free survival for Xeloda is at least equivalent to intravenous 5-fluorouracil/leucovorin (5-FU/LV), also known as the Mayo Clinic Regimen, in the adjuvant treatment of stage III colon cancer patients (or patients whose cancer has spread to the lymph nodes). The results show that treatment with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA